Aprea Therapeutics, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Aprea Therapeutics, Inc. (APRE) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 49.76 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-12
- Aprea Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 49.65M shares, a 1572.33% increase year-over-year.
- Aprea Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 2.97M shares, a 4.27% increase year-over-year.
- Aprea Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 2.85M shares, a 365.11% increase year-over-year.
- Aprea Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 612.23K shares, a 97.37% increase year-over-year.
- Aprea Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 5.93M shares, a 99.88% increase from fiscal 2024.
- Aprea Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 2.97M shares, a 357.74% increase from fiscal 2023.
- Aprea Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 648.45K shares, a 24.43% increase from fiscal 2022.
- Aprea Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 521.12K shares, a 109.04% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 49.76M shares 10-Q · filed 2026-08-12 | |||||||
| 2026-03-31 | 49.65M shares 10-Q · filed 2026-05-13 | |||||||
| 2025-12-31 | 5.93M shares 10-K · filed 2026-03-16 | |||||||
| 2025-09-30 | 3.06M shares 10-Q · filed 2025-11-12 | |||||||
| 2025-06-30 | 3.06M shares 10-Q · filed 2026-08-12 | |||||||
| 2025-03-31 | 2.97M shares 10-Q · filed 2026-05-13 | |||||||
| 2024-12-31 | 2.97M shares 10-K · filed 2026-03-16 | |||||||
| 2024-09-30 | 2.99M shares 10-Q · filed 2025-11-12 | |||||||
| 2024-06-30 | 3.00M shares 10-Q · filed 2025-08-12 | |||||||
| 2024-03-31 | 2.85M shares 10-Q · filed 2025-05-14 | |||||||
| 2023-12-31 | 648.45K shares 10-K · filed 2025-03-25 | |||||||
| 2023-09-30 | 634.62K shares 10-Q · filed 2024-11-07 | |||||||
| 2023-06-30 | 612.23K shares 10-Q · filed 2023-08-10 | |||||||
| 2023-03-31 | 612.23K shares 10-Q · filed 2024-08-12 | 610.23K shares 10-Q · filed 2023-05-15 | ||||||
| 2022-12-31 | 521.12K shares 10-K · filed 2024-03-26 | 549.24K shares 10-K · filed 2023-03-30 | ||||||
| 2022-09-30 | 621.66K shares 10-Q · filed 2023-11-09 | 9.99M shares 10-Q · filed 2022-11-09 | ||||||
| 2022-06-30 | 595.25K shares 10-Q · filed 2023-08-10 | 11.90M shares 10-Q · filed 2022-08-12 | ||||||
| 2022-03-31 | 310.20K shares 10-Q · filed 2023-05-15 | 6.20M shares 10-Q · filed 2022-05-16 | ||||||
| 2021-12-31 | 249.29K shares 10-K · filed 2024-03-26 | 4.99M shares 10-K · filed 2022-03-15 | ||||||
| 2021-09-30 | 5.12M shares 10-Q · filed 2022-11-09 | |||||||
| 2021-06-30 | 5.33M shares 10-Q · filed 2022-08-12 | |||||||
| 2021-03-31 | 5.29M shares 10-Q · filed 2022-05-16 | |||||||
| 2020-12-31 | 188.55K shares 10-K · filed 2023-03-30 | 3.77M shares 10-K · filed 2021-03-16 | ||||||
| 2020-09-30 | 3.77M shares 10-Q · filed 2021-11-08 | |||||||
| 2020-06-30 | 3.76M shares 10-Q · filed 2021-08-12 | |||||||
| 2020-03-31 | 3.85M shares 10-Q · filed 2021-05-06 | |||||||
| 2019-12-31 | 3.50M shares 10-K · filed 2022-03-15 | |||||||
| 2019-09-30 | 16.00M shares 10-Q · filed 2020-11-06 | |||||||
| 2019-06-30 | 15.79M shares 10-Q · filed 2020-08-11 | |||||||
| 2019-03-31 | 15.83M shares 10-Q · filed 2020-05-15 | |||||||
| 2018-12-31 | 14.41M shares 10-K · filed 2021-03-16 | |||||||
| 2018-09-30 | 9.69M shares 10-Q · filed 2019-11-14 | |||||||
| 2017-12-31 | 9.75M shares 10-K · filed 2020-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |